Cogent Biosciences, Inc. Quarterly Nonoperating Income (Expense) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Cogent Biosciences, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2017 to Q3 2024.
  • Cogent Biosciences, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $4.78M, a 13.9% increase year-over-year.
  • Cogent Biosciences, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $18.1M, a 13.5% increase year-over-year.
  • Cogent Biosciences, Inc. annual Nonoperating Income (Expense) for 2023 was $15.7M, a 107% increase from 2022.
  • Cogent Biosciences, Inc. annual Nonoperating Income (Expense) for 2022 was $7.6M, a 132% increase from 2021.
  • Cogent Biosciences, Inc. annual Nonoperating Income (Expense) for 2021 was $3.28M, a 55.6% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $18.1M $4.78M +$582K +13.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $17.6M $5.44M +$2.43M +80.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $15.1M $4.06M -$594K -12.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $15.7M $3.86M -$264K -6.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-26
Q3 2023 $16M $4.2M +$2.44M +139% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $13.5M $3.01M +$2.08M +224% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $11.5M $4.65M +$3.87M +493% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $7.6M $4.13M +$3.4M +467% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-26
Q3 2022 $4.2M $1.76M +$1.02M +139% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $3.18M $928K +$185K +24.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $2.99M $784K -$288K -26.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $3.28M $728K +$610K +517% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-26
Q3 2021 $2.67M $735K -$6.48M -89.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $9.15M $743K +$733K +7330% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $8.42M $1.07M +$1.03M +2181% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $7.39M $118K +$61K +107% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-15
Q3 2020 $7.33M $7.22M +$7.1M +6286% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $227K $10K -$15K -60% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $242K $47K -$103K -68.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 $345K $57K -$341K -85.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-16
Q3 2019 $686K $113K -$295K -72.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $981K $25K -$391K -94% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $1.37M $150K -$101K -40.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $1.47M $398K +$208K +109% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-26
Q3 2018 $1.27M $408K +$238K +140% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $1.03M $416K +$246K +145% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 $781K $251K +$121K +93.1% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q4 2017 $660K $190K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-28
Q3 2017 $170K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $170K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 $130K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.